Lilly’s Commitment to Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we are building upon this heritage by working to meet the diverse needs of people with diabetes and the people who care for them. Through research, collaboration and quality manufacturing, we strive to make life better for people impacted by diabetes. We offer a wide range of therapies and a continued determination to provide real solutions—from medicines and technologies to support programs and more.
Lilly’s Canadian affiliate was founded in 1938 as a result of a collaboration between Eli Lilly and Company and Banting and Best. We built our first facility in 1946, and today our Canadian headquarters is still located in Toronto, Ontario.
What Makes Us Unique
In the lab, we’re working on new treatments for people with diabetes.
In Canada, Lilly Canada and JDRF Canada have partnered since 2013 to create and support a national clinical training program. The program selects post-doctoral fellows to receive one-year grants, which enable them to further their training in translational research into type 1 diabetes. Operating through the JDRF Canadian Clinical Trial Network, the program is designed to provide the next generation of young investigators the opportunity to further engage in medical research associated with type 1 diabetes.
In developing countries around the world, we’re sharing our strength and passion with local governments and health care providers to create sustainable diabetes-management programs that meet real needs.